Literature DB >> 18398406

Management of advanced germ-cell tumors of the testis.

Aude Fléchon1, Michel Rivoire, Jean-Pierre Droz.   

Abstract

Advanced tumors of the testis are curable. Standard treatment includes chemotherapy with a combination of bleomycin, etoposide and cisplatin, followed by surgical resection of residual tumor. The number of cycles of chemotherapy needed depends on prognostic factors such as the primary site, histology, presence of visceral metastases, and serum levels of tumor markers. Patients with a favorable risk profile receive three cycles of chemotherapy, and those with increased risk receive four cycles. After chemotherapy, resection of all residual local disease and systematic retroperitoneal dissection of bulky lymph-node disease are mandatory for patients with nonseminoma germ-cell tumors. In patients with seminoma, surgery is required when residual disease is either bulky or functional on (18)fluorodeoxyglucose-PET scan. When complete resection of necrosis, teratoma and/or active germ-cell cancer has been done, no further treatment is needed. The consequences of therapy are complex: treatment could affect fertility, sexuality, metabolic status and renal and neurological function. Secondary malignancies are reported, as well as contralateral germ-cell tumors. Owing to the complexity of treatment and the multidisciplinary approach required, patients with advanced germ-cell tumors should be managed in high-volume centers with experience of treating large numbers of patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398406     DOI: 10.1038/ncpuro1101

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN: 1743-4270


  8 in total

1.  Gold-containing indoles as anticancer agents that potentiate the cytotoxic effects of ionizing radiation.

Authors:  Sandra Craig; Lei Gao; Irene Lee; Thomas Gray; Anthony J Berdis
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

Review 2.  PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  PET Clin       Date:  2015-04-24

3.  Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis.

Authors:  John P Fitzgerald; Barbara Ercole; Dipen J Parekh
Journal:  Indian J Urol       Date:  2010 Jan-Mar

4.  Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors.

Authors:  Prabhjot Singh; Siddharth Yadav; Sanjay Mahapatra; Amlesh Seth
Journal:  Indian J Urol       Date:  2016 Jan-Mar

Review 5.  Spermatogonial stem cells, infertility and testicular cancer.

Authors:  Shree Ram Singh; Ozanna Burnicka-Turek; Chhavi Chauhan; Steven X Hou
Journal:  J Cell Mol Med       Date:  2011-03       Impact factor: 5.310

6.  Diagnostic delay in oncology: a case report of metastatic seminoma.

Authors:  Norma Malavasi; Leonardo Ferrara; Claudia Fiorani; Alessia Saviola; Giuseppe Longo
Journal:  Case Rep Oncol       Date:  2011-04-06

7.  Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.

Authors:  Rashid Rasheed; Fareeda Al-Kandari; Mohammad Ghanem; Fahad Marafi; Sharjeel Usmani
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

8.  Metachronous testicular seminoma after radiotherapy and chemotherapy: a case report.

Authors:  Marcelo Di Gregorio; Marie Cécile Nollevaux; Francis Lorge; Lionel D'Hondt
Journal:  World J Surg Oncol       Date:  2016-05-16       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.